Clinical trials: Plasma Cell Tumor
Multiple Myeloma
Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma
This trial aims to evaluate the safety and efficacy of BCMA-CART in treating patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT03492268
- Testing
- BCMA-CART
- Where
- China
- Sponsor
- Bioray Laboratories
Multiple Myeloma, High-Risk Cancer
Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients
Multiple myeloma is a morbid disease associated with a poor outcome, particularly those with high-risk cytogenetics. While standard therapies have modestly improved survival in these high-risk patients, myeloma remains incurable.
- Trial name
- NCT02308280
- Testing
- Bortezomib following nonmyeloablative allogeneic transplant
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Maisonneuve-Rosemont Hospital
Multiple Myeloma
An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma
Development of new treatments for diseases such as multiple myeloma is a focus for research. The research being conducted is on treatment called Anti-KIR (1-7F9), which activates the body's own cells to kill tumor cells.
- Trial name
- NCT00552396
- Testing
- Anti-KIR (1-7F9)
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Innate Pharma
Myeloma Multiple, Myeloma, Plasma-Cell
Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients
Patients with newly diagnosed multiple myeloma (NDMM) who failed to achieve at least a minimal response (MR) after 2 cycles or a partial response (PR), after 4 cycles of a bortezomib-containing therapy, or progress on therapy…
- Conditions
- Myeloma Multiple, Myeloma, Plasma-Cell, Myeloma-Multiple, Plasma Cell Myeloma
- Trial name
- KyDaR (NCT04065789)
- Testing
- Carfilzomib, Daratumumab, Lenalidomide
- Where
- 14 sites in Israel
- Volunteers
- 41 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Multiple Myeloma and Plasma Cell Neoplasm
Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
RATIONALE: Thalidomide may stop the growth of multiple myeloma by stopping blood flow to the tumor. Prednisone may be effective in preventing relapse of multiple myeloma.
- Trial name
- NCT00006890
- Testing
- prednisone, thalidomide
- Where
- 64 sites in United States, Canada
- Volunteers
- 67 people
- Sponsor
- NCIC Clinical Trials Group
Benign and Malignant Hematologic Diseases
The American Society of Hematology (ASH) Research Registry: A Multicenter Research Registry of Patients With Hematologic Disease
This is a multicenter, retrospective and prospective, long-term registry of patients with benign or malignant hematologic diseases, whether or not these patients were or were not treated with disease-specific treatments.
- Trial name
- NCT03535220
- Testing
- Protease Inhibitors
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- American Society of Hematology
Multiple Myeloma and Plasma Cell Neoplasm
Interferon-gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma
RATIONALE: Biological therapies, such as interferon-gamma and aldesleukin, may stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00616720
- Testing
- aldesleukin, idiotype-pulsed autologous dendritic cell vaccine APC8020, recombinant interferon gamma
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
TQB2934 is an anti-Cluster of Differentiation 3 (CD3) (Early T Cell Marker)×B cell maturation antigen (BCMA) double-specific antibody，and the isoform is IgG1(Native Immunoglobulin G1), which at one end binds to the CD3 receptor…
- Trial name
- NCT07179679
- Testing
- TQB2934 injection (subcutaneous injection)
- Where
- 14 sites in China
- Volunteers
- 42 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Relapse, Refractory Multiple Myeloma
Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma
This is a multi-center, open label, uncontrolled, non-comparative phase I/II study in patients with refractory or relapsed multiple myeloma who are eligible for second, third, or fourth line therapy.
- Trial name
- NCT00306813
- Testing
- Revlimid
- Where
- Germany
- Volunteers
- 53 people
- Sponsor
- University of Wuerzburg
Multiple Myeloma
Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea
PMS period: 09Jun2017 ~ 08Jun2023 Target no.: 600patients indication: POMALYST in combination with dexamethasone is indicated in the treatment of patients with relapsed and refractory multiple myeloma who have received at least…
- Trial name
- Pomalyst PMS (NCT03288974)
- Testing
- POMALYST® (Pomalidomide)
- Where
- 33 sites in South Korea
- Volunteers
- 397 people
- Sponsor
- Celgene
Multiple Myeloma
A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy
The purpose of this study is to evaluate the safety and effectiveness of bortezomib in combination with a standard regimen of cyclophosphamide and dexamethasone.
- Trial name
- NCT00833560
- Testing
- Cyclophosphamide, Bortezomib, Dexamethasone
- Where
- 34 sites in Germany
- Volunteers
- 401 people
- Sponsor
- Janssen-Cilag G.m.b.H
Non-Hodgkin Lymphoma, Multiple Myeloma
A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China
The purpose of this study is to learn about the safety and what the body does to the medicine (Maplirpacept) when taken for the treatment of non-Hodgkin lymphoma or multiple myeloma.
- Trial name
- NCT05896774
- Testing
- Maplirpacept
- Where
- 5 sites in China
- Volunteers
- 10 people
- Sponsor
- Pfizer
Multiple Myeloma
Observational Study Evaluating the Potential Impact of Procalcitonin Testing on Care of Stemcell Transplant Recipients
An observational study in evaluating the clinical impact of procalcitonin on the care of Stem cell transplant recipient and its performance as an adjunct in the diagnosis and prognostication of Infectious processes
- Trial name
- NCT02035189
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Arkansas
Multiple Myeloma
Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma
This study will evaluate the efficacy and safety of LBH589B in adult patients with multiple myeloma who have received at least two prior therapies and are refractory to their last therapy.
- Trial name
- NCT00445068
- Testing
- LBH589
- Where
- 29 sites in United States, Germany
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma
Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple Myeloma
The primary objective is to evaluate the concordance of FDG PET/CT and total body DWI MRI sequences performed during staging and at the completion of therapy.
- Trial name
- MMR-PET-22-04 (NCT06659276)
- Where
- Italy
- Volunteers
- 83 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Multiple Myeloma
An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.
This is a Phase 1/2 study evaluating the safety and anti-tumor activity of PD 0332991 in combination with Velcade® [bortezomib] and dexamethasone in patients who have received at least one previous treatment for multiple myeloma.
- Trial name
- NCT00555906
- Testing
- Bortezomib, Dexamethasone, PD 0332991
- Where
- 19 sites in United States, Czechia and 1 more
- Volunteers
- 53 people
- Sponsor
- Pfizer
Multiple Myeloma
Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)
In this study, the investigators will analyze the long-term outcomes of remission and survival, and identify those with primary resistant disease as more likely to benefit from CTD (thalidomide, cyclophosphamide, dexamethasone)…
- Trial name
- KMM-97 (NCT01114048)
- Testing
- Thalidomide, cyclophosphamide, dexamethasone, bortezomib
- Where
- South Korea
- Volunteers
- 78 people
- Sponsor
- Chonnam National University Hospital
Multiple Myeloma
Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)
The purpose of this study is to compare the efficacy of lenalidomide and low dose dexamethasone with pembrolizumab (MK-3475) to that of lenalidomide and low dose dexamethasone without pembrolizumab in terms of progression-free…
- Trial name
- NCT02579863
- Testing
- Pembrolizumab, Lenalidomide, Dexamethasone
- Volunteers
- 310 people
- Sponsor
- Merck Sharp & Dohme LLC
Lymphoma, Non Hodgkin's Lymphoma
Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).
Some patients with multiple myeloma or lymphoma will need treatment with high dose chemotherapy to treat their condition. This potent treatment will kill many of the blood-forming cells in the bone marrow.
- Conditions
- Lymphoma, Non Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma
- Trial name
- NCT00665314
- Testing
- Plerixafor (AMD3100), Can be any registered nonpegylated form of G-CSF
- Where
- 5 sites in Germany
- Volunteers
- 5 people
- Sponsor
- Genzyme, a Sanofi Company
Hematologic Diseases, Cachexia; Cancer
WB-EMS and Nutrition in Patients With Hematological Malignancies
This study evaluates the effects of a whole-body electromyostimulation (WB-EMS) training combined with individualized nutritional support on skeletal muscle mass, body composition, muscle strength/function, quality of life…
- Conditions
- Hematologic Diseases, Cachexia; Cancer, Leukemia, Myeloma
- Trial name
- NCT03556748
- Testing
- whole-body electromyostimulation
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.